Cart
sales@molnova.com
LRRK2-IN-7
CAS No. 2307277-93-4
LRRK2-IN-7( —— )
Catalog No. M36503 CAS No. 2307277-93-4
LRRK2-IN-7 is a selective, CNS permeable and potent LRRK2 kinase inhibitor (IC50: 0.9 nM) for the study of Parkinson's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 566 | In Stock |
|
| 10MG | 905 | In Stock |
|
| 25MG | 1444 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLRRK2-IN-7
-
NoteResearch use only, not for human use.
-
Brief DescriptionLRRK2-IN-7 is a selective, CNS permeable and potent LRRK2 kinase inhibitor (IC50: 0.9 nM) for the study of Parkinson's disease.
-
DescriptionLRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase inhibitor with an IC50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAutophagy
-
TargetLRRK2
-
RecptorLRRK2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2307277-93-4
-
Formula Weight414.5
-
Molecular FormulaC24H26N6O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (241.25 mM; Ultrasonic )
-
SMILESC(#N)[C@@]1(C2(C1)CC2)C=3C=C4N(N=CC4=CC3)C=5C=C(N=CN5)N6C[C@H](C(C)(C)O)CC6
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. David A Candito, et al. Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1 H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease. J Med Chem. 2022 Dec 22;65(24):16801-16817. ?
molnova catalog
related products
-
SR 9444
SR 9444 is a small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK with IC50 of 12 nM and 99 nM respectively.
-
GSK2578215A
GSK2578215A is a highly potent, selective, BBB-permeable LRRK2 inhibitor with IC50 of 10.9 and 9.9 nM for wild-type LRRK2 and the G2019S mutant, respectively.
-
MLi-2
A potent, selective, orally available and brain-penetrant LRRK2 inhibitor with kinase IC50 of 0.76 nM, cellular IC50 of 1.4 nM (dephosphorylation of LRRK2 pSer935 LRRK2).
